Labcorp Holdings Inc. has announced the nationwide availability of the Lumipulse® pTau-217/Beta Amyloid 42 Ratio, the first blood-based in-vitro diagnostic test cleared by the U.S. Food and Drug Administration (FDA) to aid in diagnosing Alzheimer's disease. Developed by Fujirebio Diagnostics, Inc., the test offers early detection of amyloid plaques associated with Alzheimer's in adults aged 50 and older who show signs of cognitive decline. This FDA clearance marks a significant advancement in accessible and less invasive diagnostic options, as the test requires only a simple blood draw. The test is available at Labcorp's over 2,200 Patient Service Centers nationwide.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。